-
公开(公告)号：US20230210860A1
公开(公告)日：2023-07-06
申请号：US17818294
申请日：2022-08-08
发明人： Takeki UEHARA , Toru ISHIBASHI , Takao SHISHIDO , Keita FUKAO , Motoyasu OONISHI , Barry CLINCH , Jaspinder RANDHAWA
IPC分类号： A61K31/5383 , A61K31/215 , A61P31/16
CPC分类号： A61K31/5383 , A61K31/215 , A61P31/16
摘要： A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.
-
公开(公告)号：US20220008429A2
公开(公告)日：2022-01-13
申请号：US16825263
申请日：2020-03-20
发明人： Takeki UEHARA , Toru ISHIBASHI , Takao SHISHIDO , Keita FUKAO , Motoyasu OONISHI , Barry CLINCH , Jaspinder RANDHAWA
IPC分类号： A61K31/5383 , A61K31/215 , A61P31/16
摘要： A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.
-
公开(公告)号：US20240285643A1
公开(公告)日：2024-08-29
申请号：US18602656
申请日：2024-03-12
发明人： Takeki UEHARA , Toru ISHIBASHI , Takao SHISHIDO , Keita FUKAO , Motoyasu OONISHI , Barry CLINCH , Jaspinder RANDHAWA
IPC分类号： A61K31/5383 , A61K31/215 , A61P31/16
CPC分类号： A61K31/5383 , A61K31/215 , A61P31/16
摘要： A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.
-
公开(公告)号：US20200297731A1
公开(公告)日：2020-09-24
申请号：US16825263
申请日：2020-03-20
发明人： Takeki UEHARA , Toru ISHIBASHI , Takao SHISHIDO , Keita FUKAO , Motoyasu OONISHI , Barry CLINCH , Jaspinder RANDHAWA
IPC分类号： A61K31/5383 , A61K31/215 , A61P31/16
摘要： A method for treating an influenza virus infection is described. The disclosed method generally involves administering an effective amount of a compound (A), for example baloxavir marboxil, and a compound (B), for example a neuraminidase inhibor, to a subject that (1) has an influenza virus infection, (2) has been symptomatic of the influenza virus infection for no more than 96 hours, and (3) further has at least one severe influenza condition selected from the following: (a) being hospitalized due to severe influenza virus infection, (b) requiring an extension of hospitalization because of the influenza virus infection during the hospitalization, (c) having a National Early Warning Score 2 of four or more, (d) being on support for respiration, and (e) having at least one complication attributable to the influenza virus infection that necessitates hospitalization.
-
-
-
搜索结果
4 条记录 (耗时 0.017 秒)
